

Raymond F Schinazi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5596527/publications.pdf>

Version: 2024-02-01

319
papers

13,533
citations

22132

59
h-index

31818

101
g-index

336
all docs

336
docs citations

336
times ranked

14401
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Cu(I)-Catalyzed Huisgen Azide-Alkyne 1,3-Dipolar Cycloaddition Reaction in Nucleoside, Nucleotide, and Oligonucleotide Chemistry. <i>Chemical Reviews</i> , 2009, 109, 4207-4220. | 23.0 | 732 |
| 2 | Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs. <i>Chemical Reviews</i> , 2014, 114, 9154-9218. | 23.0 | 440 |
| 3 | Zika Virus Infects Human Placental Macrophages. <i>Cell Host and Microbe</i> , 2016, 20, 83-90. | 5.1 | 410 |
| 4 | Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. <i>Hepatology</i> , 2001, 33, 751-757. | 3.6 | 351 |
| 5 | COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184. | 1.8 | 302 |
| 6 | Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. <i>Chemical Reviews</i> , 2016, 116, 14379-14455. | 23.0 | 265 |
| 7 | The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. <i>Journal of Clinical Investigation</i> , 2001, 107, 449-455. | 3.9 | 255 |
| 8 | Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326. | 6.1 | 234 |
| 9 | <sc>HCV</sc> direct-acting antiviral agents: the best interferon-free combinations. <i>Liver International</i> , 2014, 34, 69-78. | 1.9 | 213 |
| 10 | Î ² -d-4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. <i>Journal of Infectious Diseases</i> , 2021, 224, 415-419. | 1.9 | 211 |
| 11 | Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-hydroxymethylthiolan-5-yl)cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). <i>Journal of Organic Chemistry</i> , 1992, 57, 2217-2219. | 1.7 | 207 |
| 12 | Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. <i>Virology</i> , 2015, 476, 196-205. | 1.1 | 202 |
| 13 | Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. <i>Journal of Biological Chemistry</i> , 2021, 297, 100770. | 1.6 | 200 |
| 14 | Design, Synthesis, and Antiviral Activity of 2-Deoxy-2-fluoro-2-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5504-5508. | 2.9 | 189 |
| 15 | Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 229-235. | 1.4 | 179 |
| 16 | Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 244-254. | 1.4 | 175 |
| 17 | Viral Sanctuaries during Highly Active Antiretroviral Therapy in a Nonhuman Primate Model for AIDS. <i>Journal of Virology</i> , 2010, 84, 2913-2922. | 1.5 | 163 |
| 18 | Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. <i>Cell</i> , 2021, 184, 460-475.e21. | 13.5 | 156 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs. <i>Journal of the American Chemical Society</i> , 1991, 113, 9377-9379. | 6.6 | 134 |
| 20 | Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <i>Liver International</i> , 2018, 38, 7-13. | 1.9 | 128 |
| 21 | Antiviral Activities and Cellular Toxicities of Modified 2',3'-Dideoxy-2'-Fluoro-3'-Didehydrocytidine Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3854-3860. | 1.4 | 120 |
| 22 | Acyclovir Is Activated into a HIV-1 Reverse Transcriptase Inhibitor in Herpesvirus-Infected Human Tissues. <i>Cell Host and Microbe</i> , 2008, 4, 260-270. | 5.1 | 119 |
| 23 | Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 72, 1247-1250. | 2.9 | 116 |
| 24 | Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 1987-1995. | 2.9 | 112 |
| 25 | Inhibition of Hepatitis C Replicon RNA Synthesis by Î ² -D-2'-deoxy-2'-fluoro-2'-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication. <i>Antiviral Chemistry and Chemotherapy</i> , 2006, 17, 79-87. | 0.3 | 110 |
| 26 | Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2'-Deoxynucleoside Triphosphates. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3465-3472. | 1.4 | 108 |
| 27 | Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. <i>Antiviral Research</i> , 2017, 144, 223-246. | 1.9 | 104 |
| 28 | Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. <i>Hepatology</i> , 2014, 60, 37-45. | 3.6 | 103 |
| 29 | Mechanism of Activation of Î ² -d-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 503-509. | 1.4 | 101 |
| 30 | Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5344-5354. | 1.4 | 99 |
| 31 | Best strategies for global HCV eradication. <i>Liver International</i> , 2013, 33, 68-79. | 1.9 | 97 |
| 32 | In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (â ²)-Î ² -d-Dioxolane-Guanosine and Suppress Resistance to 3'-Azido-3'-Deoxythymidine. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1783-1788. | 1.4 | 95 |
| 33 | Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages. <i>Journal of Biological Chemistry</i> , 2010, 285, 39380-39391. | 1.6 | 94 |
| 34 | Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. <i>Biochemical Pharmacology</i> , 1993, 45, 1540-1543. | 2.0 | 93 |
| 35 | Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds. <i>Journal of Organic Chemistry</i> , 1992, 57, 5563-5565. | 1.7 | 91 |
| 36 | 1,3-Dioxolanylpyrimidine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 30-37. | 2.9 | 90 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 519-528. | 2.9 | 89 |
| 38 | Antiretroviral Therapy in Macrophages: Implication for HIV Eradication. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 63-78. | 0.3 | 86 |
| 39 | Role of Marine Natural Products in the Genesis of Antiviral Agents. <i>Chemical Reviews</i> , 2015, 115, 9655-9706. | 23.0 | 85 |
| 40 | Nucleic acids and nucleosides containing carboranes. <i>Journal of Organometallic Chemistry</i> , 1999, 581, 156-169. | 0.8 | 84 |
| 41 | Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1977-1986. | 1.4 | 82 |
| 42 | Mechanism of Action of 1-β-d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β-d-Dioxolane Guanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 158-165. | 1.4 | 81 |
| 43 | Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 97-104. | 3.7 | 80 |
| 44 | Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. <i>Microorganisms</i> , 2021, 9, 893. | 1.6 | 80 |
| 45 | Multiple drug effect analysis with confidence interval. <i>Antiviral Research</i> , 1994, 25, 1-11. | 1.9 | 79 |
| 46 | Preparation of ribavirin analogues by copper- and ruthenium-catalyzed azide-alkyne 1,3-dipolar cycloaddition. <i>Tetrahedron</i> , 2008, 64, 9044-9051. | 1.0 | 78 |
| 47 | Human Herpesvirus 8 Open Reading Frame 21 Is a Thymidine and Thymidylate Kinase of Narrow Substrate Specificity That Efficiently Phosphorylates Zidovudine but Not Ganciclovir. <i>Journal of Virology</i> , 2000, 74, 684-692. | 1.5 | 77 |
| 48 | SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. <i>Virology</i> , 2016, 495, 92-100. | 1.1 | 77 |
| 49 | Synthesis and Anti-HIV and Anti-HBV Activities of 2-Fluoro-3-unsaturated I-Nucleosides. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1320-1328. | 2.9 | 71 |
| 50 | Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2,3-Dideoxy-5-Fluoro-3-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1300-1306. | 1.4 | 71 |
| 51 | Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 895-919. | 1.0 | 71 |
| 52 | Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. <i>PLoS Pathogens</i> , 2017, 13, e1006740. | 2.1 | 71 |
| 53 | Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites. <i>Journal of Virology</i> , 2003, 77, 10689-10694. | 1.5 | 70 |
| 54 | A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131. | 3.6 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Chutes and ladders in hepatitis C nucleoside drug development. <i>Antiviral Research</i> , 2014, 102, 119-147. | 1.9 | 69 |
| 56 | Mechanistic studies show that (âˆ™)â€¦FTCâ€¦TP is a better inhibitor of HIVâ€¦ reverse transcriptase than 3TCâ€¦TP. <i>FASEB Journal</i> , 1999, 13, 1511-1517. | 0.2 | 66 |
| 57 | Antiretroviral Monocyte Efficacy Score Linked to Cognitive Impairment in Hiv. <i>Antiviral Therapy</i> , 2012, 17, 1233-1242. | 0.6 | 66 |
| 58 | Characterization of Î²- <sc>d</sc> - <i>N</i> ⁴ -Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 64 |
| 59 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4428-4431. | 1.0 | 63 |
| 60 | Antiviral Activity of Nucleoside Analogues against Norovirus. <i>Antiviral Therapy</i> , 2012, 17, 981-991. | 0.6 | 63 |
| 61 | Significance of endangered and threatened plant natural products in the control of human disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16832-16837. | 3.3 | 63 |
| 62 | Towards <sc>HBV</sc> curative therapies. <i>Liver International</i> , 2018, 38, 102-114. | 1.9 | 63 |
| 63 | Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 7349-7354. | 1.5 | 61 |
| 64 | Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophosphate Dehydrogenase (IMPDH) - the Major Therapeutic Target. <i>Current Medicinal Chemistry</i> , 2004, 11, 887-900. | 1.2 | 60 |
| 65 | In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1139-1144. | 1.4 | 60 |
| 66 | The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. <i>Neurobiology of Disease</i> , 2016, 92, 137-143. | 2.1 | 60 |
| 67 | Boron Containing Pyrimidines, Nucleosides, and Oligonucleotides for Neutron Capture Therapy. <i>Nucleosides & Nucleotides</i> , 1994, 13, 849-880. | 0.5 | 58 |
| 68 | Predicting Zika virus structural biology: Challenges and opportunities for intervention. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 118-126. | 0.3 | 58 |
| 69 | Synthesis, Structureâˆ™Activity Relationships, and Drug Resistance of Î²-d-3â€¦-Fluoro-2â€¦,3â€¦-Unsaturated Nucleosides as Anti-HIV Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3399-3408. | 2.9 | 57 |
| 70 | Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives. <i>Medicinal Chemistry Research</i> , 2012, 21, 3741-3749. | 1.1 | 57 |
| 71 | Synthesis and antiviral activity of 2â€¦-deoxy-2â€¦-fluoro-2â€¦-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 1712-1715. | 1.0 | 56 |
| 72 | Treatment as prevention and cure towards global eradication of hepatitis C virus. <i>Trends in Microbiology</i> , 2013, 21, 625-633. | 3.5 | 56 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Combined Antiviral Effect of Interferon and Acyclovir on Herpes Simplex Virus Types 1 and 2. <i>Antimicrobial Agents and Chemotherapy</i> , 1981, 19, 672-674. | 1.4 | 55 |
| 74 | Asymmetric synthesis of enantiomerically pure (âˆ™)-(1â€²R,4â€²R)-dioxolane-thymine and its anti-HIV activity.. <i>Tetrahedron Letters</i> , 1991, 32, 3791-3794. | 0.7 | 55 |
| 75 | Effect of Î²-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. <i>Biochemical Pharmacology</i> , 1996, 52, 1577-1584. | 2.0 | 54 |
| 76 | Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta.-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents. <i>Journal of Medicinal Chemistry</i> , 1985, 28, 741-748. | 2.9 | 53 |
| 77 | Synthesis and Biological Evaluation of 2â€²,3â€²-Didehydro-2â€²,3â€²-dideoxy-5- fluorocytidine (D4FC) Analogues:Â Discovery of Carbocyclic Nucleoside Triphosphates with Potent Inhibitory Activity against HIV-1 Reverse Transcriptase1. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 859-867. | 2.9 | 51 |
| 78 | Facile Purification of Honokiol and Its Antiviral and Cytotoxic Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3426-3427. | 2.9 | 51 |
| 79 | Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. <i>Antiviral Research</i> , 2006, 71, 322-334. | 1.9 | 51 |
| 80 | Advances in nucleoside monophosphate prodrugs as anti-HCV agents. <i>Antiviral Therapy</i> , 2010, 15, 935-950. | 0.6 | 51 |
| 81 | Approaches to hepatitis C treatment and cure using NS5A inhibitors. <i>Infection and Drug Resistance</i> , 2014, 7, 41. | 1.1 | 51 |
| 82 | SAMHD1 Functions and Human Diseases. <i>Viruses</i> , 2020, 12, 382. | 1.5 | 51 |
| 83 | Structureâˆ™Activity Relationships of 2â€²-Deoxy-2â€²,2â€²-difluoro-l-erythro-pentofuranosyl Nucleosides. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3635-3644. | 2.9 | 50 |
| 84 | Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, . | 1.5 | 49 |
| 85 | DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1394-1401. | 1.4 | 48 |
| 86 | l-2â€²,3â€²-Didehydro-2â€²,3â€²-dideoxy-3â€²-fluoronucleosides:â€‰ Synthesis, Anti-HIV Activity, Chemical and Enzymatic Stability, and Mechanism of Resistance. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3245-3256. | 2.9 | 46 |
| 87 | Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome. <i>PLoS ONE</i> , 2010, 5, e9948. | 1.1 | 46 |
| 88 | Cellular pharmacology and biological activity of 5-carboranyl-2â€²-deoxyuridine. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 1113-1120. | 0.4 | 45 |
| 89 | Carboranyl Oligonucleotides. 2. Synthesis and Physicochemical Properties of Dodecathymidylate Containing 5-(o-Carboran-1-yl)-2'-deoxyuridine. <i>Journal of the American Chemical Society</i> , 1994, 116, 7494-7501. | 6.6 | 45 |
| 90 | Substrates and Inhibitors of SAMHD1. <i>PLoS ONE</i> , 2017, 12, e0169052. | 1.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Repurposing Nucleoside Analogs for Human Coronaviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, . | 1.4 | 45 |
| 92 | Simultaneous Quantification of Intracellular Natural and Antiretroviral Nucleosides and Nucleotides by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2010, 82, 1982-1989. | 3.2 | 44 |
| 93 | Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10031-10043. | 2.9 | 44 |
| 94 | 3-Azido-2,3-Dideoxyuridine (AZDDU): Comparative Pharmacokinetics with 3-Azido-3-Deoxythymidine (AZT) in Monkeys. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 219-228. | 0.5 | 43 |
| 95 | Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks. <i>Antiviral Therapy</i> , 2000, 5, 95-104. | 0.6 | 43 |
| 96 | Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1986, 29, 151-154. | 2.9 | 42 |
| 97 | Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. <i>Journal of Pharmacokinetics and Biopharmaceutics</i> , 1990, 13, 206-211. | 0.5 | 40 |
| 98 | Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3483-3490. | 1.4 | 40 |
| 99 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 407-421. | 2.6 | 40 |
| 100 | Synthesis, Biotransformation, and Pharmacokinetic Studies of 9-(2-deoxy-2-fluoro-5-azido-6-azidopurine-9-yl)-6-azidopurine: A Prodrug for Ara-A Designed To Utilize the Azide Reduction Pathway. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 5202-5207. | 2.9 | 38 |
| 101 | The 3-Azido Group Is Not the Primary Determinant of 3-Azido-3-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1. <i>Journal of Biological Chemistry</i> , 2005, 280, 29047-29052. | 1.6 | 38 |
| 102 | Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2-deoxyuridine; 5-iodo-2-deoxycytidine; 5-iodo-5-amino-2,5-dideoxyuridine. <i>Journal of Medicinal Chemistry</i> , 1979, 7, 1-34. | | 37 |
| 103 | Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8596-8601. | 3.3 | 37 |
| 104 | dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages. <i>Retrovirology</i> , 2014, 11, 63. | 0.9 | 36 |
| 105 | Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. <i>Journal of Neuroinflammation</i> , 2019, 16, 182. | 3.1 | 36 |
| 106 | Ribonucleotide reductase inhibitors suppress SAMHD1 activity enhancing cytarabine efficacy. <i>EMBO Molecular Medicine</i> , 2020, 12, e10419. | 3.3 | 35 |
| 107 | Cell-Based and Animal Models for Hepatitis B and C Viruses. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 99-114. | 0.3 | 34 |
| 108 | HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor 2-Deoxy-2,3-Dideoxy-2,3-Didehydro-5-Fluorocytidine (Reverset, ϵ). <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 49-59. | 3 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Cellular Pharmacology and Potency of HIV-1 Nucleoside Analogs in Primary Human Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1262-1269. | 1.4 | 34 |
| 110 | Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. <i>Future Microbiology</i> , 2015, 10, 1773-1782. | 1.0 | 34 |
| 111 | Synthesis, Antiviral Activity, and Mechanism of Drug Resistance of 2',3'-Didehydro-2',3'-dideoxy-2'-fluorocarboxylic Nucleosides. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3736-3748. | 2.9 | 32 |
| 112 | Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages. <i>Virology</i> , 2016, 491, 106-114. | 1.1 | 32 |
| 113 | Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 95-104. | 2.9 | 31 |
| 114 | Metabolism of the Anti-Hepatitis C Virus Nucleoside 2'-d-N ⁴ -Hydroxycytidine in Different Liver Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4636-4642. | 1.4 | 30 |
| 115 | Combinations of 2'-Methylcytidine Analogues with Interferon- β and Triple Combination with Ribavirin in the Hepatitis C Virus Replicon System. <i>Antiviral Chemistry and Chemotherapy</i> , 2008, 19, 25-31. | 0.3 | 30 |
| 116 | 2'-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3445-3458. | 2.9 | 30 |
| 117 | Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 30 |
| 118 | Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. <i>Antiviral Therapy</i> , 1999, 4, 21-28. | 0.6 | 30 |
| 119 | Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5'-amino derivatives. <i>Journal of Medicinal Chemistry</i> , 1979, 22, 1273-1277. | 2.9 | 29 |
| 120 | A chemiluminescence immunoassay for evaluation of <i>Cryptosporidium parvum</i> growth in vitro. <i>FEMS Microbiology Letters</i> , 1996, 136, 251-256. | 0.7 | 29 |
| 121 | Derivatives of 3,6-disulfonato-1,8-naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells. <i>Journal of Cellular Biochemistry</i> , 1993, 51, 446-457. | 1.2 | 28 |
| 122 | Synthesis and Potent Anti-HIV Activity of 3-Fluoro-3'-Unsaturated Cytidine. <i>Organic Letters</i> , 2001, 3, 4177-4180. | 2.4 | 28 |
| 123 | Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses <i>In Vitro</i> and in Humanized Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 28 |
| 124 | Mechanistic and Kinetic Differences between Reverse Transcriptases of Vpx Coding and Non-coding Lentiviruses. <i>Journal of Biological Chemistry</i> , 2015, 290, 30078-30086. | 1.6 | 26 |
| 125 | From HCV To HBV Cure. <i>Liver International</i> , 2017, 37, 73-80. | 1.9 | 26 |
| 126 | Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 Spike Mutations Associated with Variants of Concern. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0144621. | 1.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Anti-hepatitis C Virus Activity of Novel 2-Deoxy-2-methyl-4-azido Pyrimidine Nucleoside Phosphoramidate Prodrugs. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 99-106. | 0.3 | 25 |
| 128 | The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 169-174. | 1.0 | 24 |
| 129 | Synthesis of 2,3-dideoxy-3-fluoro-l-ribonucleosides as potential antiviral agents from d-sorbitol. <i>Carbohydrate Research</i> , 2000, 328, 49-59. | 1.1 | 24 |
| 130 | Interactions of enantiomers of 2,3-didehydro-2,3-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. <i>Antiviral Research</i> , 2002, 56, 189-205. | 1.9 | 24 |
| 131 | The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. <i>Molecular Biology International</i> , 2012, 2012, 1-8. | 1.7 | 24 |
| 132 | Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. <i>Clinics in Liver Disease</i> , 2016, 20, 737-749. | 1.0 | 24 |
| 133 | New Classes of Fluorinated L-Nucleosides; Synthesis and Antiviral Activity. <i>Nucleosides & Nucleotides</i> , 1999, 18, 537-540. | 0.5 | 23 |
| 134 | Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. <i>Antiviral Research</i> , 2002, 55, 141-150. | 1.9 | 23 |
| 135 | Anti-HIV Activity of (2R,4R)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)-thymine against Drug-Resistant HIV-1 Mutants and Studies of Its Molecular Mechanism. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3949-3952. | 2.9 | 23 |
| 136 | Simian immunodeficiency virus macaque models of HIV latency. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 57-61. | 1.5 | 23 |
| 137 | 2-Chloro,2-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5424-5437. | 2.9 | 23 |
| 138 | ANTI-HBV SPECIFIC 2-L-DEOXYNUCLEOSIDES. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2001, 20, 597-607. | 0.4 | 22 |
| 139 | Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 115-125. | 0.3 | 22 |
| 140 | Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3488-3491. | 1.0 | 22 |
| 141 | Jak Inhibitors Modulate Production of Replication Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells. <i>Pathogens and Immunity</i> , 2017, 2, 199. | 1.4 | 22 |
| 142 | Pharmacokinetics of (-)-beta-D-Dioxolane Guanine and Prodrug (-)-beta-D-2,6-Diaminopurine Dioxolane in Rats and Monkeys. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1625-1630. | 0.5 | 21 |
| 143 | From d-to l-nucleoside analogs as antiviral agents. <i>Advances in Antiviral Drug Design</i> , 1999, , 1-68. | 0.7 | 21 |
| 144 | Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2031-2034. | 1.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses. <i>Retrovirology</i> , 2014, 11, 111. | 0.9 | 21 |
| 146 | Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis. <i>Oncotarget</i> , 2015, 6, 11047-11060. | 0.8 | 21 |
| 147 | Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 668-673. | 1.0 | 21 |
| 148 | Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex. <i>Nucleic Acids Research</i> , 2018, 46, 9711-9725. | 6.5 | 21 |
| 149 | Ribonucleotide incorporation in yeast genomic DNA shows preference for cytosine and guanosine preceded by deoxyadenosine. <i>Nature Communications</i> , 2020, 11, 2447. | 5.8 | 21 |
| 150 | Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. <i>Tetrahedron</i> , 2011, 67, 5487-5493. | 1.0 | 20 |
| 151 | Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. <i>Protein Science</i> , 2019, 28, 1664-1675. | 3.1 | 20 |
| 152 | Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 98-101. | 1.5 | 20 |
| 153 | Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100045. | 1.7 | 20 |
| 154 | Pharmacodynamics of (S)-2',3'-Dideoxy-3'-Thiacytidine in Chronically Virus-Infected Woodchucks Compared to Its Pharmacodynamics in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2804-2809. | 1.4 | 19 |
| 155 | Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3'-Azido-2',3'-Dideoxypurine Nucleosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3715-3719. | 1.4 | 19 |
| 156 | Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5'-triphosphates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7094-7098. | 1.0 | 19 |
| 157 | Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 34-42. | 0.9 | 19 |
| 158 | HIV nucleoside reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114554. | 2.6 | 19 |
| 159 | Synthesis and Biological Properties of 5-o-Carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2583-2588. | 2.9 | 18 |
| 160 | Tissue Disposition of 5-o-Carboranyluracil: A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 291-306. | 0.4 | 18 |
| 161 | Analysis of Multiply Spliced Transcripts in Lymphoid Tissue Reservoirs of Rhesus Macaques Infected with RT-SHIV during HAART. <i>PLoS ONE</i> , 2014, 9, e87914. | 1.1 | 18 |
| 162 | Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. <i>FASEB Journal</i> , 1993, 7, 1070-1080. | 0.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Comparative Pharmacokinetics of Racivir [®] , (R)-2,3-Dideoxy-5-Fluoro-3-Thiacytidine in Rats, Rabbits, Dogs, Monkeys and HIV-Infected Humans. <i>Antiviral Chemistry and Chemotherapy</i> , 2005, 16, 117-127. | 0.3 | 17 |
| 164 | Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4241-4250. | 1.4 | 17 |
| 165 | Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6325-6330. | 1.0 | 17 |
| 166 | Anti-human immunodeficiency virus type-1 (HIV-1) and anti-hepatitis B virus (HBV) activities of (2,3-dideoxy-2-fluoro-2-L-threo-pentofuranosyl)nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 877-880. | 1.0 | 16 |
| 167 | In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of 2,3-Dideoxy-2,3-Dideoxy-5-Fluorocytidine. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3930-3932. | 1.4 | 16 |
| 168 | Synthesis and anti-HIV activity of (R)-2-d-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (R)-2-d-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. <i>Antiviral Research</i> , 2007, 75, 198-209. | 1.9 | 16 |
| 169 | Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase. <i>Molecular Pharmacology</i> , 2012, 82, 125-133. | 1.0 | 16 |
| 170 | Synthesis and Evaluation of 2,6-Modified Purine 2-Methyl Ribonucleosides as Inhibitors of HCV Replication. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 17-22. | 1.3 | 16 |
| 171 | Interplay of ancestral non-primate lentiviruses with the virus-restricting SAMHD1 proteins of their hosts. <i>Journal of Biological Chemistry</i> , 2018, 293, 16402-16412. | 1.6 | 16 |
| 172 | Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. <i>Metabolism Open</i> , 2021, 10, 100090. | 1.4 | 16 |
| 173 | Cellular Pharmacology of D-d4FC, a Nucleoside Analogue Active against Drug-Resistant HIV. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 39-47. | 0.3 | 15 |
| 174 | Synthesis of 2-Enantiomers of 4-Hydroxy-3-Deoxy-Pyrimidine Nucleosides and Their Evaluation against Bovine Viral Diarrhoea Virus and Hepatitis C Virus in Cell Culture. <i>Antiviral Chemistry and Chemotherapy</i> , 2004, 15, 43-55. | 0.3 | 15 |
| 175 | Practical considerations for developing nucleoside reverse transcriptase inhibitors. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e183-e193. | 4.0 | 15 |
| 176 | Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 15 |
| 177 | Potent in vitro activity of 2-D-4-chloromethyl-2-deoxy-2-fluorocytidine against Nipah virus. <i>Antiviral Research</i> , 2020, 175, 104712. | 1.9 | 15 |
| 178 | Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 351-361. | 1.1 | 14 |
| 179 | Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. <i>Antiviral Research</i> , 2002, 56, 115-127. | 1.9 | 14 |
| 180 | Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. <i>Antiviral Research</i> , 2004, 62, 57-64. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | A CRISPR/Cas9 approach reveals that the polymerase activity of DNA polymerase β is dispensable for HIV-1 infection in dividing and nondividing cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 14016-14025. | 1.6 | 14 |
| 182 | Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. <i>Oncotarget</i> , 2017, 8, 94040-94053. | 0.8 | 14 |
| 183 | Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2165-2170. | 1.0 | 14 |
| 184 | Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. <i>Viruses</i> , 2019, 11, 1039. | 1.5 | 14 |
| 185 | Pharmacokinetics of the Antiviral Agent β -D-2,3-Didehydro-2,3-Dideoxy-5-Fluorocytidine in Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 381-384. | 1.4 | 14 |
| 186 | Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern. <i>IScience</i> , 2022, 25, 103968. | 1.9 | 14 |
| 187 | Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 693-696. | 1.0 | 13 |
| 188 | Pharmacokinetics of 5-Carboranyl-2-deoxyuridine in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1697-1699. | 1.6 | 13 |
| 189 | Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir. <i>Nucleosides & Nucleotides</i> , 1997, 16, 2079-2092. | 0.5 | 13 |
| 190 | Cellular Pharmacology of the D- and L-Enantiomers of β -5-o-Carboranyl-2-deoxyuridine. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2000, 19, 691-702. | 0.4 | 13 |
| 191 | ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1712, 81-91. | 1.4 | 13 |
| 192 | Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-(β -D-Dioxolane)Thymine Triphosphate. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2078-2084. | 1.4 | 13 |
| 193 | Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. <i>Antiviral Research</i> , 2009, 83, 317-323. | 1.9 | 13 |
| 194 | Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. <i>Antiviral Therapy</i> , 2010, 15, 185-192. | 0.6 | 13 |
| 195 | Synthesis and evaluation of 3-azido-2,3-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 60-64. | 1.0 | 13 |
| 196 | Synthesis of purine modified 2-C-methyl nucleosides as potential anti-HCV agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6788-6792. | 1.0 | 13 |
| 197 | Synthesis and evaluation of novel potent HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4864-4868. | 1.0 | 13 |
| 198 | Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4101-4105. | 1.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 904-910. | 1.0 | 13 |
| 200 | Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. <i>Viruses</i> , 2021, 13, 114. | 1.5 | 13 |
| 201 | Viral Decay Kinetics in the Highly Active Antiretroviral Therapy-Treated Rhesus Macaque Model of AIDS. <i>PLoS ONE</i> , 2010, 5, e11640. | 1.1 | 13 |
| 202 | A Short Synthesis of 2,3-Didehydro-3-deoxythymidine. <i>Nucleosides & Nucleotides</i> , 1993, 12, 149-155. | 0.5 | 12 |
| 203 | A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy. <i>Nucleosides & Nucleotides</i> , 1997, 16, 2133-2150. | 0.5 | 12 |
| 204 | A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (2S)-2,3-Dideoxy-3-Thiacytidine. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2077-2080. | 1.4 | 12 |
| 205 | Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 2759-2766. | 1.4 | 12 |
| 206 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of 1-3-azido-2,3-dideoxypurine nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3832-3844. | 2.6 | 12 |
| 207 | Synthesis and anti-HCV activity of a series of 2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5296-5299. | 1.0 | 12 |
| 208 | Carboranyl Oligonucleotides for Antisense Technology and Boron Neutron Capture Therapy of Cancers. <i>ACS Symposium Series</i> , 1994, , 169-182. | 0.5 | 11 |
| 209 | Review Hepatitis B Virus Resistance to Lamivudine and its Clinical Implications. <i>Antiviral Chemistry and Chemotherapy</i> , 2002, 13, 143-155. | 0.3 | 11 |
| 210 | Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2618-2624. | 1.4 | 11 |
| 211 | Antiviral and Cellular Metabolism Interactions between Dextrovalicitabine and Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2130-2135. | 1.4 | 11 |
| 212 | Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3845-3851. | 2.6 | 11 |
| 213 | Evaluation of Single and Combination Therapies with Tenofovir Disoproxil Fumarate and Emtricitabine <i>In Vitro</i> and in a Robust Mouse Model Supporting High Levels of Hepatitis B Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6186-6191. | 1.4 | 11 |
| 214 | Randomized, Double-Blind, Multicenter Safety and Efficacy Study of Rifalazil Compared with Azithromycin for Treatment of Uncomplicated Genital Chlamydia trachomatis Infection in Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4014-4019. | 1.4 | 11 |
| 215 | Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4659-4669. | 1.4 | 11 |
| 216 | Discovery of a Series of 2-Fluoro, 2-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1859-1874. | 2.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Structural and Antiviral Studies of the Human Norovirus GII.4 Protease. <i>Biochemistry</i> , 2019, 58, 900-907. | 1.2 | 11 |
| 218 | Potent Antiviral Effect of Raltegravir in HIV-1-Infected Adults following a Single Oral Dose. <i>Antiviral Therapy</i> , 2004, 9, 529-536. | 0.6 | 11 |
| 219 | Development of a Novel Mouse Model to Evaluate Drug Candidates against Hepatitis B Virus. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 213-223. | 0.3 | 10 |
| 220 | Development of a Population Simulation Model for HIV Monotherapy Virological Outcomes Using Lamivudine. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 329-341. | 0.3 | 10 |
| 221 | Pharmacokinetics of the Antiviral Agent Î²-d-2-Deoxy-2-Fluoro-2-C-Methylcytidine in Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2877-2882. | 1.4 | 10 |
| 222 | Enhanced Antiretroviral Therapy in Rhesus Macaques Improves RT-SHIV Viral Decay Kinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3927-3933. | 1.4 | 10 |
| 223 | Synthesis and antiviral evaluation of 2,2,3,3-tetrafluoro nucleoside analogs. <i>Tetrahedron Letters</i> , 2017, 58, 642-644. | 0.7 | 10 |
| 224 | GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition. <i>Viruses</i> , 2022, 14, 132. | 1.5 | 10 |
| 225 | Biotransformation and pharmacokinetics of prodrug 9-(Î²-d-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(Î²-d-1,3-dioxolan-4-yl)guanine in mice. <i>Antiviral Research</i> , 1997, 35, 187-193. | 1.9 | 9 |
| 226 | Synthesis and Biological Properties of the Four Optical Isomers of 5-o-Carboranyl-2,3-didehydro-2,3-dideoxyuridine. <i>Nucleosides & Nucleotides</i> , 1998, 17, 711-727. | 0.5 | 9 |
| 227 | Synthesis and anti-HIV activity of 5-haloethynyl and 5-(1,2-dihalo)vinyl analogues of AZT and FLT. <i>Tetrahedron</i> , 2008, 64, 4444-4452. | 1.0 | 9 |
| 228 | Approaches for the Development of Antiviral Compounds: The Case of Hepatitis C Virus. <i>Handbook of Experimental Pharmacology</i> , 2009, , 25-51. | 0.9 | 9 |
| 229 | Synthesis of 6-imino-5-tetrahydro-1H-2-pyrrolylidenhexahydro-2,4-pyrimidinediones as intermediates for the synthesis of C-azanucleosides. <i>Tetrahedron Letters</i> , 2010, 51, 231-233. | 0.7 | 9 |
| 230 | Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 556-564. | 1.5 | 9 |
| 231 | Residual Viremia in an RT-SHIV Rhesus Macaque HAART Model Marked by the Presence of a Predominant Plasma Clone and a Lack of Viral Evolution. <i>PLoS ONE</i> , 2014, 9, e88258. | 1.1 | 9 |
| 232 | Synthesis and antiviral evaluation of 2,3-dideoxy-2,3-difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosides. <i>Heterocyclic Communications</i> , 2015, 21, 315-327. | 0.6 | 9 |
| 233 | Synthesis and anti-HCV activity of Î²-d-2-deoxy-2-Î±-chloro-2-Î²-fluoro and Î²-d-2-deoxy-2-Î±-bromo-2-Î²-fluoro nucleosides and their phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 664-676. | 1.4 | 9 |
| 234 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 31, 115952. | 1.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency. <i>Frontiers in Immunology</i> , 2021, 12, 720697. | 2.2 | 9 |
| 236 | Elimination of Aicardiâ€“GoutiÃ“res syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication. <i>Journal of Biological Chemistry</i> , 2022, 298, 101635. | 1.6 | 9 |
| 237 | In Vitro Evaluation of Anticryptosporidial Agents Using MDCK Cell Culture and Chemiluminescence Immunoassay. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 87S-87S. | 0.8 | 8 |
| 238 | Comparison of Physicochemical and Biological Properties of (<i>o</i>-Carboran-1-yl)methylphosphonate and Methylphosphonate Oligonucleotides. <i>Nucleosides & Nucleotides</i> , 1997, 16, 1503-1505. | 0.5 | 8 |
| 239 | Synthesis of Six-Membered Nucleoside Analogs. Part 1: Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System. <i>Nucleosides & Nucleotides</i> , 1997, 16, 403-416. | 0.5 | 8 |
| 240 | Synthesis and Antiviral Activities of Enantiomeric 1-[2-(Hydroxymethyl) Cyclopropyl] Methyl Nucleosides. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2000, 19, 253-268. | 0.4 | 8 |
| 241 | Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3385-3388. | 1.0 | 8 |
| 242 | Sonication-Assisted Synthesis of (<i>E</i>)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs. <i>ChemistrySelect</i> , 2016, 1, 3108-3113. | 0.7 | 8 |
| 243 | Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 8 |
| 244 | Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 8 |
| 245 | Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126639. | 1.0 | 8 |
| 246 | 7-Deaza-7-fluoro-2â€“C-methyladenosine inhibits Zika virus infection and viral-induced neuroinflammation. <i>Antiviral Research</i> , 2020, 180, 104855. | 1.9 | 8 |
| 247 | Metabolism of Nucleosides and Nucleotides Prodrugs. <i>Current Pharmaceutical Design</i> , 2018, 23, 6984-7002. | 0.9 | 8 |
| 248 | The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4854-4864. | 2.9 | 8 |
| 249 | 2 â€“ ,3 â€“ -Didehydro-2 â€“ ,3 â€“ -dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2159-2162. | 1.0 | 7 |
| 250 | Pharmacology and Pharmacokinetics of the Antiviral Agent Î²- d -2â€“,3â€“-Dideoxy-3â€“-Oxa-5-Fluorocytidine in Cells and Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2589-2597. | 1.4 | 7 |
| 251 | The Boronâ€“Neutron Capture Agent Î²-d-5-o-Carboranyl-2â€“-deoxyuridine Accumulates Preferentially in Dividing Brain Tumor Cells. <i>Journal of Neuro-Oncology</i> , 2005, 74, 275-280. | 1.4 | 7 |
| 252 | Lack of Pharmacokinetic Interaction between Amdoxovir and Reduced- and Standard-Dose Zidovudine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1248-1255. | 1.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Synthesis and Biological Evaluation of 4 <i>C</i> ,3 <i>O</i> -Propylene-Linked Bicyclic Nucleosides. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 7390-7399. | 1.2 | 7 |
| 254 | Selection and Characterization of HIV-1 with a Novel S68 Deletion in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2054-2060. | 1.4 | 7 |
| 255 | Anti-HIV-1 screening of (2 <i>E</i>)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones. <i>Medicinal Chemistry Research</i> , 2014, 23, 402-407. | 1.1 | 7 |
| 256 | Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases. <i>Tetrahedron Letters</i> , 2015, 56, 3587-3590. | 0.7 | 7 |
| 257 | Synthesis of (2 <i>S</i>)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination. <i>Journal of Organic Chemistry</i> , 2017, 82, 13171-13178. | 1.7 | 7 |
| 258 | Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages. <i>Retrovirology</i> , 2018, 15, 69. | 0.9 | 7 |
| 259 | Synthesis of 2-fluoro-substituted and 2,6-modified purine 2 <i>â</i> ² ,3 <i>â</i> ² -dideoxy-2 <i>â</i> ² ,3 <i>â</i> ² -difluoro-d-arabinofuranosyl nucleosides from d-xylose. <i>Tetrahedron</i> , 2019, 75, 2037-2046. | 1.0 | 7 |
| 260 | Structural and functional characterization explains loss of dNTPase activity of the cancer-specific R366C/H mutant SAMHD1 proteins. <i>Journal of Biological Chemistry</i> , 2021, 297, 101170. | 1.6 | 7 |
| 261 | In Vitro Expression of mRNA Coding For a <i>Cryptosporidium parvum</i> Oocyst Wall Protein. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 84s-85S. | 0.8 | 6 |
| 262 | Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2 <i>â</i> ² ,3 <i>â</i> ² ,5 <i>â</i> ² -tri- O -acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 235-240. | 1.1 | 6 |
| 263 | In silico study supports the efficacy of a reduced dose regimen for stavudine. <i>Antiviral Research</i> , 2011, 92, 372-377. | 1.9 | 6 |
| 264 | Scaleable processes for the synthesis of (â ²)-Î ² -d-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (â ²)-Î ² -d-2-aminopurine dioxolane (APD). <i>Tetrahedron</i> , 2012, 68, 5738-5743. | 1.0 | 6 |
| 265 | Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient. <i>Hepatology</i> , 2018, 67, 2051-2054. | 3.6 | 6 |
| 266 | Efficient pre-catalytic conformational change of reverse transcriptases from SAMHD1 non-counteracting primate lentiviruses during dNTP incorporation. <i>Virology</i> , 2019, 537, 36-44. | 1.1 | 6 |
| 267 | Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages. <i>Retrovirology</i> , 2019, 16, 29. | 0.9 | 6 |
| 268 | Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery. <i>Journal of Biological Chemistry</i> , 2020, 295, 13432-13443. | 1.6 | 6 |
| 269 | Moving Fast Toward Hepatitis B Virus Elimination. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 115-138. | 0.8 | 6 |
| 270 | RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2021, 2, 1-1. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. <i>Journal of Natural Products</i> , 2021, 84, 3001-3007. | 1.5 | 6 |
| 272 | Synthesis of Cyclopentanyl Carbocyclic 5-Fluorocytosine (($\hat{\wedge}$)-5-Fluorocarbodine) Using a Facially Selective Hydrogenation Approach. <i>Journal of Organic Chemistry</i> , 2013, 78, 723-727. | 1.7 | 5 |
| 273 | Synthesis and antiviral evaluation of 2-amino-6-carbamoyl-purine dioxolane nucleoside derivatives and their phosphoramidates prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6665-6671. | 1.4 | 5 |
| 274 | Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors. <i>Journal of Molecular Modeling</i> , 2015, 21, 282. | 0.8 | 5 |
| 275 | Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4+ T cells. <i>Virology</i> , 2015, 485, 313-321. | 1.1 | 5 |
| 276 | Anti-human immunodeficiency activity of novel 2-arylpyrrolidine analogs. <i>Medicinal Chemistry Research</i> , 2017, 26, 101-108. | 1.1 | 5 |
| 277 | Disparate effects of Cytotoxic Chemotherapy on the Antiviral Activity of Antiretroviral Therapy: Implications for Treatments of HIV-Infected Cancer Patients. <i>Antiviral Therapy</i> , 2019, 24, 177-186. | 0.6 | 5 |
| 278 | HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability. <i>Aids</i> , 2018, 32, 1613-1623. | 1.0 | 5 |
| 279 | Synthesis of 4 $\hat{\wedge}$ -Substituted-2 $\hat{\wedge}$ -Deoxy-2 $\hat{\wedge}$ - $\hat{\pm}$ -Fluoro Nucleoside Analogs as Potential Antiviral Agents. <i>Molecules</i> , 2020, 25, 1258. | 1.7 | 5 |
| 280 | Covid $\hat{\wedge}$ 19 will not $\hat{\wedge}$ magically disappear $\hat{\wedge}$. Why access to widespread testing is paramount. <i>American Journal of Hematology</i> , 2021, 96, 174-178. | 2.0 | 5 |
| 281 | Disproportionate presence of adenosine in mitochondrial and chloroplast DNA of <i>Chlamydomonas reinhardtii</i> . <i>IScience</i> , 2021, 24, 102005. | 1.9 | 5 |
| 282 | Potent antiviral effect of reversion in HIV-1-infected adults following a single oral dose. <i>Antiviral Therapy</i> , 2004, 9, 529-36. | 0.6 | 5 |
| 283 | Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies. <i>ImmunoHorizons</i> , 2022, 6, 144-155. | 0.8 | 5 |
| 284 | Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine. , 2003, , 451-484. | | 4 |
| 285 | Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. <i>Antiviral Research</i> , 2015, 115, 75-82. | 1.9 | 4 |
| 286 | Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6566-6578. | 2.5 | 4 |
| 287 | Novel 1 $\hat{\wedge}$ -homo- <i>N</i> -2 $\hat{\wedge}$ -deoxy- $\hat{\pm}$ -nucleosides: synthesis, characterization and biological activity. <i>RSC Advances</i> , 2020, 10, 15815-15824. | 1.7 | 4 |
| 288 | Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV Study. <i>Antiviral Therapy</i> , 2019, 24, 567-579. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675. | 0.6 | 4 |
| 290 | Cloning and Expression of Sporozoite and Oocyst <i>Cryptosporidium parvum</i> Recombinant Proteins.. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 83S-83S. | 0.8 | 3 |
| 291 | Emtricitabine. <i>Drugs</i> , 2003, 63, 2425-2426. | 4.9 | 3 |
| 292 | 4-Acyl-Modified D-2',3'-Dideoxy-5-Fluorocytidine Nucleoside Analogues with Improved Antiviral Activity. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 81-90. | 0.3 | 3 |
| 293 | Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. <i>Antiviral Research</i> , 2014, 101, 62-67. | 1.9 | 3 |
| 294 | Editorial overview: Antiviral strategies. <i>Current Opinion in Virology</i> , 2016, 18, v-vi. | 2.6 | 3 |
| 295 | FRI-157-Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation. <i>Journal of Hepatology</i> , 2019, 70, e457. | 1.8 | 3 |
| 296 | Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 261-269. | 1.0 | 3 |
| 297 | Intracellular metabolism and potential cardiotoxicity of a 1 ² -D-2 TM -C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 204-224. | 0.4 | 3 |
| 298 | Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. <i>Molecules</i> , 2020, 25, 4868. | 1.7 | 3 |
| 299 | Viral protein X reduces the incorporation of mutagenic noncanonical rNTPs during lentivirus reverse transcription in macrophages. <i>Journal of Biological Chemistry</i> , 2020, 295, 657-666. | 1.6 | 3 |
| 300 | Viral Pharmacodynamic Model for (1 ²)-2',3'-Dideoxy-5-Fluoro-3'-Thiacytidine (Emtricitabine) in Chronically Infected Woodchucks. <i>Antiviral Chemistry and Chemotherapy</i> , 2002, 13, 165-176. | 0.3 | 2 |
| 301 | N 4-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2005, 24, 1209-1214. | 0.4 | 2 |
| 302 | Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV. <i>PLoS ONE</i> , 2014, 9, e86997. | 1.1 | 2 |
| 303 | Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3711-3715. | 1.0 | 2 |
| 304 | Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2017, 36, 66-82. | 0.4 | 2 |
| 305 | Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 671-687. | 0.4 | 2 |
| 306 | Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking viral protein X. <i>Journal of Biological Chemistry</i> , 2020, 295, 16975-16986. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model. <i>Journal of NeuroVirology</i> , 2020, 26, 838-845. | 1.0 | 2 |
| 308 | The Base Component of 3'-Azido-2',3'-Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3758-3764. | 1.4 | 1 |
| 309 | Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al. <i>Clinical Infectious Diseases</i> , 2020, 73, e3980-e3981. | 2.9 | 1 |
| 310 | Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines. <i>Molecular Diversity</i> , 2021, 25, 2045-2052. | 2.1 | 1 |
| 311 | Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1555-1566. | 1.0 | 1 |
| 312 | Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus. <i>Infectious Disorders - Drug Targets</i> , 2018, 18, 224-232. | 0.4 | 1 |
| 313 | Diastereoselective Synthesis of 2'-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication. <i>ACS Omega</i> , 2022, 7, 1452-1461. | 1.6 | 1 |
| 314 | HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?. <i>Journal of the International AIDS Society</i> , 2016, 19, 21008. | 1.2 | 0 |
| 315 | A new oxygen modification cyclooctaoxygen binds to nucleic acids as sodium crown complex. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 785-794. | 1.1 | 0 |
| 316 | Response to Correspondence: Baricitinib as Treatment of COVID-19 Friend or Foe of the Pancreas? Cerda-Contreras et.al. <i>Clinical Infectious Diseases</i> , 2020, 73, e3978-e3979. | 2.9 | 0 |
| 317 | CD81 receptor expression in human cells. , 2003, , 485-492. | | 0 |
| 318 | <i>In silico</i> design of a novel nucleotide antiviral agent by free energy perturbation. <i>Chemical Biology and Drug Design</i> , 2022, , . | 1.5 | 0 |
| 319 | Identification of Botanical Viral Entry Inhibitors for SARS-CoV-2. <i>FASEB Journal</i> , 2022, 36, . | 0.2 | 0 |